Literature DB >> 24519162

Photodynamic Therapy of Malignant Ovarian Tumours Cultivated on CAM.

M S Ismail1, U Torsten, C Dressler, J E Diederichs, S Hüske, H Weitzel, H P Berlien.   

Abstract

The disappointing results with either surgery alone and/or chemotherapy in the treatment of malignant ovarian tumours have led to an increased interest in additional treatment schedules. Photodynamic therapy (PDT), a modality involving the use of a photosensitising drug and activating light, is being used increasingly as a local treatment for neoplastic lesions. The synthesis and evaluation of new photosensitisers for the treatment of gynaecological lesions and malignancies continues to be an active area of investigation for proper application of the photodynamic process in the gynaecological field. The effect of PDT using methylene blue (free and combined with liposomes) as a photosensitiser for treating human ovarian malignant tumours cultivated on the chorioallantoic membrane was evaluated. Two days after PDT, the treated implanted tumours were markedly decreased in size. Areas of necrosis with black coloration, dryness and eschar formation were observed. Five days after PDT, tumour remission was clearly observed in all the treated tumours. Photodynamic therapy using methylene blue (aqueous and coupled with liposomes) is effective for treating the ovarian malignancies and it will be capable of achieving complete eradication of visible tumours in patients with superficial lesions.

Entities:  

Year:  1999        PMID: 24519162     DOI: 10.1007/s101030050028

Source DB:  PubMed          Journal:  Lasers Med Sci        ISSN: 0268-8921            Impact factor:   3.161


  9 in total

Review 1.  The chick chorioallantoic membrane (CAM) as a versatile patient-derived xenograft (PDX) platform for precision medicine and preclinical research.

Authors:  Logan C DeBord; Ravi R Pathak; Mariana Villaneuva; Hsuan-Chen Liu; Daniel A Harrington; Wendong Yu; Michael T Lewis; Andrew G Sikora
Journal:  Am J Cancer Res       Date:  2018-08-01       Impact factor: 6.166

Review 2.  The chicken chorioallantoic membrane model in biology, medicine and bioengineering.

Authors:  Patrycja Nowak-Sliwinska; Tatiana Segura; M Luisa Iruela-Arispe
Journal:  Angiogenesis       Date:  2014-08-20       Impact factor: 9.596

Review 3.  Applications of the Chick Chorioallantoic Membrane as an Alternative Model for Cancer Studies.

Authors:  Pei-Yu Chu; Angele Pei-Fern Koh; Jane Antony; Ruby Yun-Ju Huang
Journal:  Cells Tissues Organs       Date:  2021-03-29       Impact factor: 2.208

4.  The CAM Assay as an Alternative In Vivo Model for Drug Testing.

Authors:  Regine Schneider-Stock; Domenico Ribatti
Journal:  Handb Exp Pharmacol       Date:  2021

Review 5.  Patient Derived Chicken Egg Tumor Model (PDcE Model): Current Status and Critical Issues.

Authors:  Aoi Komatsu; Kotaro Matsumoto; Tomoki Saito; Manabu Muto; Fuyuhiko Tamanoi
Journal:  Cells       Date:  2019-05-10       Impact factor: 6.600

6.  Establishment of xenografts of urological cancers on chicken chorioallantoic membrane (CAM) to study metastasis.

Authors:  Junhui Hu; Moe Ishihara; Arnold I Chin; Lily Wu
Journal:  Precis Clin Med       Date:  2019-10-01

Review 7.  Microvascular Experimentation in the Chick Chorioallantoic Membrane as a Model for Screening Angiogenic Agents including from Gene-Modified Cells.

Authors:  Donna C Kennedy; Barbara Coen; Antony M Wheatley; Karl J A McCullagh
Journal:  Int J Mol Sci       Date:  2021-12-31       Impact factor: 5.923

8.  Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane.

Authors:  Moe Ishihara; Junhui Hu; Xiaoyu Zhang; YongHyeon Choi; Anthony Wong; Celine Cano-Ruiz; Rongwei Zhao; Ping Tan; Jonathan L Tso; Lily Wu
Journal:  J Vis Exp       Date:  2020-02-08       Impact factor: 1.424

Review 9.  Animal models for photodynamic therapy (PDT).

Authors:  Zenildo Santos Silva; Sandra Kalil Bussadori; Kristianne Porta Santos Fernandes; Ying-Ying Huang; Michael R Hamblin
Journal:  Biosci Rep       Date:  2015-09-28       Impact factor: 3.840

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.